FRX Related StreetInsider.com Reports
-
Carl Icahn's Q1 13F Reveals Little New
-
BMO Capital Starts Forest Laboratories (FRX) at Underperform
-
Forest Labs (FRX), Almirall Report Positive Results from 2nd AUGMENT COPD Phase III
-
Forest Laboratories, Inc. (FRX) Tops Q4 EPS by 1c, Sales Miss Views
-
Forest Laboratories (FRX) 'Day of Reckoning' Not Far Off
-
Trading Radar for 04/23: Apple (AAPL), AT&T (T), United Tech (UTX), Yum! (YUM), VMware (VMW) Report
-
AstraZeneca's (AZN) Best Chance to Regain Profitability? One Major Acquisition...
-
Notable Analyst Rating Changes 01/31: (FB) (VALE) (AJG) Upgraded; (RF) (PCLN) (VELT) Downgraded
-
Janney Montgomery Scott Starts Forest Laboratories (FRX) at Buy
-
Ironwood (IRWD) Updates on Q4 Sales; LINZESS Breaks $19M Mark
-
Forest Laboratories, Inc. (FRX) Misses Q3 EPS by 7c; Eases FY13 Outlook
-
Trading Radar for 01/15: Lennar (LEN), Linear Technology (LLTC), ADTRAN (ADTN), Interactive Brokers (IBKR) Report
-
Icahn's Transocean (RIG) Stake Has Management Shaking In Boots
-
Goldman Sachs Upgrades Forest Laboratories (FRX) to Neutral
-
Cantor Fitzgerald's Conviction Calls For 2013
-
Forest Labs (FRX) Enters Settlement Over Generic BYSTOLIC Tabs
-
Cowen Upgrades Forest Laboratories (FRX) to Outperform
-
Citi Starts Forest Laboratories (FRX) at Buy
-
Notable Analyst Rating Changes 11/09: (ISIS) (FAST) (MRO) Upgraded; (PSX) (MDRX) (CSCO) Downgraded
-
Mizuho Securities Starts Forest Laboratories (FRX) at Buy
-
Forest Labs (FRX) Enters Settlement Over BYSTOLIC Tabs
-
Forest Laboratories, Inc. (FRX) Posts Q2 EPS of 50c; Revs Heavy
-
Trading Radar for 10/16: Coca-Cola (KO), Goldman Sachs (GS), J&J (JNJ), IBM (IBM), Intel (INTC) Report
-
Is AstraZeneca (AZN) Preserving Cash for a Forest Labs (FRX) Bid?
-
Forest Laboratories (FRX) Submits New Drug Application for Levomilnacipran for the Treatment of Major Depressive Disorder
-
Forest Labs (FRX) Pushed to New 52-Week High on Volume
-
Alzheimer's Treatment Pharmas on Watch as Merz Gets Positive CHMP Opinion for Memantine MAA
-
FDA Approves AEROSPAN, Forest Labs (FRX) Assumes Development and Commercialization
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Christmas Comes Early
-
Jefferies Maintains a 'Buy' on Forest Laboratories (FRX); Quickly Moving Into Pole Position
-
Cantor Fitzgerald Reiterates a 'Sell' on Ironwood Pharmaceuticals (IRWD); Shares Still Overvalued
-
Streetinsider.com's Hot Lunchtime Reads 08/30: (YGE) (FB) (SGYP) (S) (YELP)
-
UPDATE: Synergy Pharma (SGYP) Higher on Linzess Approval (IRWD) (FRX)
-
FDA Approves IBS-C Treatment Linzess (IRWD) (FRX)
-
FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation
-
UPDATE: Ironwood (IRWD), Forest (FRX) Win FDA Approval for Linzess
-
Forest Labs (FRX) Adopts Poison Pill Provision; Declares Preferred Purchase Right Distribution
-
Forest Labs (FRX) Affirms Icahn Nominee Elected to Board Following Certified Inspection
-
"Patent Cliff" Takes Toll on Drug Sales
-
Forest Labs (FRX) Says One of Icahn's Nominees Elected to Board
-
Carl Icahn wins 1 seat on Forest Laboratories (FRX) board
-
Icahn Sends Letter to Forest Labs (FRX) Board; Says Statement 'Mischaracterizes' Position, Intentions
-
JPMorgan Downgrades Forest Laboratories (FRX) to Neutral
-
Carl Icahn Sends Letter to Forest Labs (FRX) Holders; Pleased with ISS Support of Nominees
-
UBS Maintains a 'Neutral' on Forest Laboratories (FRX); An Aclidinium Approval As Expected
-
Forest Labs (FRX) Shares Tick Higher Following Headline of FDA Approval for Chronic Lung Disease Treatment
-
Forest Labs (FRX) Wins FDA Approval for COPD Treatment -Bloomberg
-
Needham & Company Maintians a 'Hold' on Forest Laboratories (FRX); Q1 Review; Reviewing FDA Calendar
-
Icahn Highlights Qualifications on Board Nominees in Response to Forest Labs (FRX)
-
Baird Maintains a 'Neutral' on Forest Laboratories (FRX); Q1 a Net-Neutral Event
Back to FRX Stock Lookup
